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COMPARATIVE OUTCOMES OF NONABLATIVE AND ABLATIVE ALLOGE-
NEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS
WITH HEMATOLOGIC MALIGNANCIES YOUNGER THAN 50 YEARS
Kim, H.-G., Kim, I., Kim, B.-S., Kim, J.-S., Hong, Y.-S., Yoon, S.-S.,
Lee, J.-S., Park, S., Kim, B.K. Department of Internal Medicine, Seoul
National University, College of Medicine, Seoul, Korea.
Nonablative conditioning in allogeneic stem cell transplantation
has been performed for reducing transplantation-related compli-
cations. In this study, we compared outcomes of nonablative and
ablative conditioning in younger adults less than 50 years with
hematologic malignancies. From Jan. 2001 until Dec. 2004, 105
adult patients younger than 50 years old with hematologic malig-
nancies were transplanted fromHLA-matched donors, using nona-
blative conditioning (n  35) or ablative conditioning (n  70).
The median ages of nonablative and ablative patients were 36 and
33 years, respectively (P  .014). 17% of nonablative patients
received a prior myeloablative transplant, whereas none of the
ablative patients did (P  .001). Neutrophil engraftment (ie, time
to absolute neutrophil count 	0.5  109/L) was faster in the
nonablative group (median, 10 days; range, 0-21 days) than in the
ablative group (median, 18 days; range, 11-38 days) (P  .0001).
The time to reach a platelet count of more than 20 109/L was 13
days (range, 0-35 days) in the nonablative group, compared with 22
days (range, 9-110 days) in the ablative group (P  .006). The
incidence of grades 2 to 4 acute graft-versus-host disease was
similar in patients of nonablative and ablative groups, 17% vs.
24%, respectively (P  .40). 39% of patients in the nonablative
group and 36% of patients in the ablative group developed chronic
graft-versus-host disease (P  .76). The cumulative incidences of
day 100 nonrelapse mortality were 18% in nonablative patients and
21% in ablative patients (P  .88). Overall survival rates for
nonablative and ablative patients were 43% and 35% at 2 years
(P  .72), respectively. Two-year progression free survival rates of
nonablative and ablative patients were both 35%. In conclusion,
nonablative transplantation showed comparable outcomes with ab-
lative transplantation for younger patients less than 50 years with
hematological malignancies.
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DEVELOPMENT OF A UNIVERSAL AND EFFECTIVE MYELOID PROGEN-
ITOR CELL THERAPEUTIC FOR TREATING NEUTROPENIA
Christensen, J.L.1, Smith-Berdan, S.1, Wahedi, M.1, Danenberg, E.1,
Gille, D.1, Brown, W.2, Fong, T.1, Domen, J.1 1. Cellerant Therapeu-
tics, San Carlos, CA; 2. Stanford University, Department of Medicine,
Stanford, CA.
Ablative conditioning for hematopoietic cell transplantation and
accidental or therapeutic exposure to high levels of radiation or
chemicals will result in signiﬁcant loss of myeloid cells, erythro-
cytes, and platelets leading to morbidity and mortality. Myeloid
progenitors freshly puriﬁed from mouse bone marrow have been
found to prevent fatal fungal and bacterial infections in neutro-
penic mice (Blood. 2002;100:4660-4667), as well as protect against
exposure to lethal levels of radiation (J Clin Invest. 2002;109:1579-
1585). However, fresh isolation of cells for wide spread clinical use
is impractical and unfeasible for treating large patient populations.
Our goal is to develop a novel universal treatment that provides
temporary but effective recovery of these blood cells with a stan-
dardized manufactured myeloid progenitor cell therapeutic. We
have developed a method for generating in vitro and cryopreserv-
ing large numbers of myeloid progenitors (MP) from puriﬁed
hematopoietic stem cells (HSC) in serum-free conditions. These
culture-derived MPs are as effective as freshly isolated myeloid
progenitors in preventing death from invasive aspergillosis in neu-
tropenic animals, increasing survival in allogeneic transplantation,
and providing radioprotection following lethal irradiation. Cul-
ture-derived MPs are effective across allogeneic barriers, and do
not cause GVHD. Furthermore, infusion of cryopreserved, pooled
MPs derived from several MHC disparate donors is as effective as
MPs derived from a single allogeneic donor. These results suggest
that our in vitro generated and cryopreserved MPs may be an
effective bridging therapy during hematopoietic recovery. We are
currently developing methods to generate MPs from highly en-
riched human hematopoietic stem cells for clinical testing.
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CELL DOSE AND GRAFT VERSUS HOST DISEASE (GVHD) AFFECT SUR-
VIVAL IN ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLAN-
TATION (ALLOPBSCT) FOLLOWING NON-MYELOABLATIVE (NM) CON-
DITIONING: A SINGLE CENTER EXPERIENCE
Johnson, J.L.1,2, Vusirikala, M.1,2, Chinratanalab, W.1, Brandt, S.1,2,
Shyr, Y.2, Shakhtour, B.2, Kassim, A.2, Jagasia, M.2, Morgan, D.1,2,
Ruffner, K.1,2, Stein, R.2, Greer, J.2, Schuening, F.2, Goodman, S.1,2 1.
Nashville Veterans Administration Medical Center, Nashville, TN; 2.
Vanderbilt University Medical Center, Nashville, TN.
AlloSCT utilizing NM conditioning is hypothesized to minimize
the toxicity of myeloablative regimens while harnessing a potent
graft vs malignancy effect. We sought to identify factors related to
survival in a retrospective analysis of 37 male patients (pts) who
underwent alloPBSCT from HLA-matched related donors be-
tween 8/00 and 5/05 at the Nashville VAMC. All pts received NM
conditioning with 90 mg/m2 ﬂudarabine and 200 cGy TBI.
GVHD prophylaxis consisted of cyclosporine and mycophenolate
mofetil. The median age was 55 years (range 41-66), and the
diseases transplanted included: MM (12); AML (6); CML (2); CLL
(7); NHL (8); and HD (1). The mean cell doses infused were 7.7
(range 3.4-15.4)  106 CD34/kg and 29.1 (range 10.1-64.1) 
107 CD3/kg. Most pts did not become neutropenic; among 17
(46%) who did, the median time to ANC 	500 was 19 days (range
14-29). Primary graft failure occurred in 1 patient. Of evaluable pts
with chimerism data, median time to 100% donor chimerism was
day 28 for CD33 and day 180 for CD3. AGVHD occurred
in 26/37 (70%) pts (grade I in 10 and grades II-IV in 16), and
cGVHD occurred in 16/31 (52%); 5 pts developed extensive
cGVHD. 9 pts required donor lymphocyte infusion for disease
progression. 100-day non-relapse mortality was 14% (all from
aGVHD); 1 death prior to day100 was from disease progression.
Beyond day 100, 10 pts died from disease progression, 2 from
infection and 3 from unknown causes. Kaplan-Meier probabilities
for overall survival (OS) and progression free survival (PFS) at one
year were 56% and 50%, respectively. OS at 3 years was 31%. In
univariate analysis, the development of cGVHD signiﬁcantly corre-
lated with OS (P  .05) and PFS (P  .04). Pts with grades 0-I
aGVHD experienced signiﬁcantly longer OS and PFS compared to
pts with grades II-IV aGVHD (P  .03). Although CD34 and
CD3 doses showed no signiﬁcant association with development of
cGVHD, higher doses of both cell types were associated with all
grades of aGVHD (P .05) and showed a trend toward development
of higher grades of aGVHD (grades II-IV versus grades 0-I) (P .06).
Survival after NM alloSCT in this population is encouraging, al-
though disease progression remains an area for future study. Our
results suggest CD34 and CD3 cell doses should be optimized to
minimize aGVHD as a cause of early death. The correlation between
cGVHD and survival likely reﬂects a graft vs. malignancy effect.
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BONE MARROW TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA
FROM DONOR WITH GAUCHER DISEASE FOLLOWED BY ENZYME RE-
PLACEMENT THERAPY (ERT)
Mrsic, M., Labar, B., Potocki, K., Fumic, K., Stern-Padovan, R.,
Bogdanic, V. University Hospital Zagreb, Department of Internal Med-
icine, Zagreb, Croatia.
Before the era of Enzyme Replacement Therapy (ERT), HSCT
despite limited availability (HLA identical donor) has been used for
the treatment of Gaucher disease. Case Report: Diagnosis of
standard risk acute myeloid leukemia in 32 year old female was
established in May 2002. Disease remission was obtained in June
2002. HLA tests were performed and an HLA identical brother
was found. He had a long history of anemia bone pain. Splenec-
tomy was done in his childhood. According to the medical docu-
mentation Gaucher disease was mentioned but never diagnosed.
Because availability of ERT and severe underlying disease (acute
leukemia) we decided to proceed with HSCT despite donor un-
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derlying disease (Mb. Gaucher). Donor examination prior to do-
nation was as follows: hemoglobin level 110 g/L, platelet 148 
109/L, WBC in normal range. Bone MR revealed typical changes
for Gaucher disease. Beta glucosidase level was low ( 2.4 nmol/
h/mg of protein) and chitotriosidase very high (60000 nmol/h/ml
of plasma). There were no other signs of other diseases and we
decided to proceed with HSCT. Patients were conditioned with a
standard Bu  Cy regimen followed by graft versus host disease
(GVHD) prevention with a combination of CSPMTX. Marrow
harvesting was complicated due to the lacking to collect sufﬁcient
number of cells and two leukaphereses were performed. After
hematopoietic stem cell infusion recovery was successful and the
patient was discharged form the hospital on day 35. There were
no signs of acute or chronic GVHD. Complete chimerism was
obtained from marrow and blood. There were no signs of Gaucher
disease in bone marrow. Donor ERT was started immediately after
hematopoietic stem cell donation. Recipient ERT was started 3
months after hematopoietic stem cell infusion. There were no
signs of Gaucher disease in the recipient. Due to administrative
reasons ERT was stopped after 2 years of treatment. Recent ex-
aminations showed that the recipient started to develop signs of
Gaucher disease. ERT was introduced again in the recipient. Con-
clusions: This case report shows that hematopoietic stem cells of
a donor with Gaucher disease can be successfully transplanted.
Harvesting could be complicated due to the insufﬁcient number of
collected cells. Enzyme replacement therapy (ERT) can prevent
the development of Gaucher disease in the recipient transplanted
with Gaucher marrow.
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DONOR SPECIFIC TRANSFUSION AND EITHER METHOTREXATE OR
CD154-BLOCKADE BEFORE TRANSPLANT IMPROVES RATES OF SUS-
TAINED ENGRAFTMENT IN DOGS CONDITIONED WITH 100 CGY TOTAL
BODY IRRADIATION
Jochum, C.1, Beste, M.1, Zellmer, E.1, Harkey, M.A.1, Graves, S.S.1,
Storb, R.1,2 1. Fred Hutchinson Cancer Research Center, Seattle, WA; 2.
University of Washington, Seattle, WA.
Introduction: Stable mixed chimerism can be established in dogs
given a sublethal dose of 200 cGy total body irradiation (TBI)
before and immunosuppression with mycophenolate mofetil
(MMF) or rapamycin combined with cyclosporine (CSP) after
marrow transplantation. When the TBI dose is reduced to 100
cGy, only transient engraftment is observed (11 of 11 dogs rejected
their grafts). Here we asked whether stable engraftment after 100
cGy TBI could be accomplished by reducing host immune respon-
siveness using either the antimetabolite methotrexate (MTX) or an
anti-CD154 antibody, which blocks the CD40-CD154 T-cell co-
stimulatory pathway in conjunction with infusions of donor pe-
ripheral blood mononuclear cells (PBMC). Methods: One group
of recipients was given iv infusions of 5 106 PBMC/kg from their
intended DLA-identical littermate marrow donors on days 5 and
3 followed by 0.4 mg/kg MTX on days 4 and 2 (group 1). A
second group received a single iv injection of 5 mg/kg anti-CD154
antibody (day 5) followed one day later by donor PBMC (com-
bined iv/sc injections of 107 PBMC/kg) (group 2). Antibody dosing
was based on studies of suppression of mixed leucocyte culture
reactivity in vitro and in vivo pharmacokinetics. 100 cGy TBI
(delivered at 7 cGy/min) was given to all dogs on day 0 followed by
infusion of a median of 3.46  108 marrow cells/kg. Postgrafting
immunosuppression consisted of MMF (10 mg/kg, BID, days 0 to
28) and CSP (15 mg/kg BID, days 1 to 35) in all dogs. Results:
All six dogs in group 1 showed initial engraftment. Two of the six
showed sustained engraftment while 4 dogs rejected their grafts at
weeks 5, 8 and 10, respectively, and survived with autologous
recovery. Five of six dogs in group 2 were evaluable, while one dog
was too early to be evaluated. All ﬁve evaluable dogs had initial
engraftment. Three of the ﬁve dogs continued to show stable
mixed donor/host hematopoietic chimerism, one for 	16 weeks
and two for 	26 weeks. Two dogs rejected their grafts, 9 and 12
weeks after transplantation, respectively, and recovered autologous
hematopoiesis. Conclusions: Donor PBMC infusions and pre-
transplant host immunosuppression with either MTX or anti-
CD154 antibody were partially effective in assuring sustained en-
graftment of DLA-identical marrow after non-myeloablative
conditioning with 100 cGy TBI combined with MMF and CSP.
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SUCCESSFUL USE OF AN ANTI-TUMOR NECROSIS FACTOR-ALPHA (TNF-	)
MONOCLONAL ANTIBODY (INFLIXIMAB) FOR THE TREATMENT OF CYTO-
MEGALOVIRUS (CMV)–INDUCED PNEUMONITIS AFTER ALLOGENEIC HAE-
MOPOIETIC STEM CELL TRANSPLANTATION (Allo-HSCT)
Garcı´a Sepu´lveda, C.A., Ovilla Martı´nez, R. Hospital Angeles Lomas
Haematology Department and Stem Cell Transplant Unit, Huixquilu-
can, Mexico.
Several pro-inﬂammatory cytokines have been shown to play a
fundamental role in the genesis and perpetuation of adaptive immune
responses. Recent investigations into the biological relevance of such
cytokines in systemic inﬂammatory responses have demonstrated a
protective role for them during the early phase of infection. However,
the activity of inﬂammatory cytokines after the pathogenic challenge
has been resolved has also been shown to represent a deleterious,
often lethal, role in which unspeciﬁc inﬂammatory reactions (but not
the infectious agent) overwhelm the body. Recently, a monoclonal
antibody capable of blocking the effects of TNF-
 (inﬂiximab) has
been proven capable of modulating systemic inﬂammatory responses.
Here we describe the successful treatment of adult respiratory distress
syndrome caused by CMV with inﬂiximab in a recipient of allo-
HSCT. The patient involved was a 35 year old male that received an
HLA-compatible unrelated peripheral blood HSCT for chronic my-
elogenous leukemia in June 2001. The patient was subjected to my-
eloablative conditioning (fractionated total body irradiation  cyclo-
phosphamide) and received cyclosporin A and methotrexate for
GvHD prophylaxis. On day34 the patient complained of chest pain
and developed dyspnea, fever and chills; CT scan revealed the pres-
ence of bilateral diffuse micronodular interstitial inﬁltrates. Lung
biopsy and culture demonstrated the presence of inclusion bodies
suggestive of CMV infection while the presence of other bacterial,
viral and fungal agents was ruled out. Qualitative CMV-speciﬁc PCR
subsequently conﬁrmed the diagnosis at titers of 313.8 pg/mL. The
patient received IV immunoglobulins  ganciclovir therapy and sup-
portive care. By day45 the patient continued with fever and showed
worsening lung edema (became polypneic, attained less than 75%
blood-oxygen saturations in spite of non-invasive mechanical ventila-
tory support and developed hypoxic encephalopathy). On day48 the
patient received the ﬁrst of two 200 mg doses of inﬂiximab. By day
50 the patient was feverless, had less dyspnea and achieved blood
oxygen saturations above 90% at ambient air and without mechanical
ventilatory support. Both physical examination and chest x-rays re-
vealed a dramatic clinical improvement by day 53. Here we discuss
a therapeutical role for TNF-
 blocking monoclonal antibody (inﬂix-
imab) in the management of post-infectious pathogen-induced sys-
temic inﬂammatory responses.
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ALLOTRANSPLANTATION WITH REDUCED INTENSITY CONDITIONING
THAT INCLUDES ALEMTUZUMAB LESSENS TRANSPLANT-RELATED
MORTALITY AND INCIDENCE OF RELAPSE IN PATIENTS WITH HIGH-
RISK MYELOID DISEASES
Bigelow, C.L., Elkins, S.L., Hardy, C.L., Files, J.C. University of
Mississippi Medical Center, Jackson, MS.
Patients with high risk myeloid disease can be transplanted with
reduced intensity conditioning regimens that maximize remission
duration while minimizing transplant-related mortality. Incidence
of survival, relapse, tempo of engraftment and incidence of grades
I-II and III-IV acute GVHD were evaluated. Three conditioning
regimens have been utilized: ﬂudarabine 30 mg/m2  5 days,
melphalan 140 mg/m2  1 day in all groups and alemtuzumab 20
mg/d  5 days (group 1),  3 days (group 2) and  2 days (group
3). Fifteen patients (median age 48, range 24-58 years) were in the
study. Twelve patients had AML, two had CML and one had
MDS. Six patients were in CR at time of transplant and nine had
relapsed or refractory disease. Patients were consecutively assigned
to group 1 (seven patients), group 2 (ﬁve patients) and group 3
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